InterMune to Hold Conference Call to Discuss Phase III Clinical Trial Results Of Actimmune in IPF on Wednesday, August 28
BRISBANE, Calif., Aug 27, 2002 /PRNewswire-FirstCall via COMTEX/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the Company will announce Phase III clinical trial results of Actimmune (interferon gamma-1b) in the treatment of idiopathic pulmonary fibrosis tomorrow, Wednesday, August 28, at 8:00 a.m. EDT, and host a live conference call and webcast at 9:00 a.m. EDT following the release.
To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international). A replay of the webcast and teleconference will be available approximately three hours after the call for two business days. To access the replay, please call 1-800-642-1687 (U.S.) or 706-645-9291 (international), and enter the conference ID# 5479918.
To access the webcast, please log on to the Company's website at intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. |
